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Diabetes is a consequence of a decrease on functional b-cell mass. We have recently demonstrated that
epoxypukalide (Epoxy) is a natural compound with beneﬁcial effects on primary cultures of rat islets. In this study, we
extend our previous investigations to test the hypothesis that Epoxy protects b-cells and improves glucose metabolism
in STZ-induced diabetic mice.
We used 3-months old male mice that were treated with Epoxy at 200 mg/kg body weight. Glucose intolerance was
induced by multiple intraperitoneal low-doses of streptozotocin (STZ) on 5 consecutive days. Glucose homeostasis was
evaluated measuring plasma insulin levels and glucose tolerance. Histomorphometry was used to quantify the number
of pancreatic b-cells per islet. b-cell proliferation was assessed by BrdU incorporation, and apoptosis by TUNEL staining.
Epoxy treatment signiﬁcantly improved glucose tolerance and plasma insulin levels. These metabolic changes were
associated with increased b-cell numbers, as a result of a two-fold increase in b-cell proliferation and a 50% decrease in
b-cell death.
Our results demonstrate that Epoxy improves whole-body glucose homeostasis by preventing pancreatic b-cell
death due to STZ-induced toxicity in STZ-treated mice.
Introduction
Diabetes is one of the most devastating chronic diseases in the
world.1,2 A major hallmark of diabetes is hyperglycemia, a condi-
tion related to abnormal insulin secretion by pancreatic b-cells.3
In type 1 diabetes (T1D), b-cell mass decreased by »70-100%,
whereas in type 2 diabetes (T2D) up to 65%.4-6 In both forms of
the disease, pancreatic b-cell apoptosis is augmented by incom-
pletely understood mechanisms that, at least in part, involve
b-cell damage and inflammatory infiltrates within pancreas.3-5
In view of the relevance of diabetes disease worldwide, increas-
ing interest has been raised to search for new compounds with
therapeutic effects on b-cell abnormal insulin secretion and
normalize glycemia in T1D and T2D patients. Thus, intensive
research has been focusing on biochemical substances from plant
and marine sources with therapeutic potential. Following this
line of work, we recently reported that epoxypukalide (Epoxy), a
member of the furanocembranolide family isolated from the gor-
gonian Leptogorgia setacea, exhibited protective effects on pancre-
atic b-cells ex vivo without altering glucose-stimulated insulin
secretion.7 We demonstrated that Epoxy induced b-cell replica-
tion in pancreatic b-cell lines (INS1 832/13) and primary rat
b-cell cultures through a mechanism involving activation of
ERK1/2 signaling pathway and upregulation of cell cycle activa-
tors such as cyclin D2 and cyclin E. In addition, Epoxy showed
protection against basal and cytokine-mediated b-cell death in
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primary cultures of rat islets.7 These results spurred us to spread
the notion that Epoxy may be translated into a new treatment for
diabetes prevention.
Experimental animal models of diabetes exhibit b-cell abnor-
mal insulin secretion and elevated blood glucose levels, which are
associated with oxidative stress and inflammation. Streptozotocin
(STZ) is a natural compound with toxic effects on b-cells, cur-
rently used in single large doses or multiple low doses to induce
diabetes in mice. Thus, the STZ-induced diabetic mouse model
is widely used for the screening of new compounds with protec-
tive properties against b-cell death and hypoglycemic effects.8,9
This work was designed to test the hypothesis that in vivo
administration of Epoxy exerts protective effects on pancreatic
b-cells and glucose homeostasis in a STZ-induced diabetic
mouse model.
Methods
Animals
Male Swiss OF1 (Clr:OF1), were used for the study. Mice
were 3 months-old of age at the beginning of the study.
They were bred and housed in the Animal Facilities of the
School of Medicine, University of Valladolid (UVa), Spain.
Mice were fed standard rodent chow and water ad libitum in
ventilation-controlled cages in a 12-hour light/dark cycle.
Experimental procedures were approved by the Animal Care
and Use Committee of the UVa in accordance with the
European and Spanish Guidelines for the Care and Use of
Mammals in Research.
Study design
Mice were randomly assigned into 2 groups: “Control” (vehi-
cle D 0.001% DMSO) (N D 8) and “Epoxy” (200 mg epoxypu-
kalide/kg body weight) (N D 10). Both groups received daily IP
(intraperitoneal) injections of vehicle or Epoxy for 30 days before
they were treated with multiple low dose-STZ to study if Epoxy
was having a protective effect on pancreatic b-cells. IP injections
of freshly prepared STZ at dose of 50 mg/kg body weight (in
0.01 M citrate buffer, pH 4.5) for 5 consecutive days.
Metabolic characterization was performed when glucose
intolerance was identified. Mice were IP injected with BrdU
(50 mg/kg) 16 hours before been euthanized.
Plasma biochemistry
Blood samples were obtained from mice under non-fasting
conditions. Blood was collected from the tail vein into capil-
lary tubes precoated with potassium-EDTA (Sarstedt, Ger-
many) for the preparation of plasma. Non-fasting plasma
insulin levels were measured using ultrasensitive mouse
ELISA assay according to manufacturer’s instructions (Merco-
dia, Sweeden).
Glucose tolerance test
IP-GTT (intraperitoneal glucose tolerance test) was per-
formed as previously described.10 Briefly, mice were fasted for
16 hours and injected intraperito-
neally with glucose at 2 g/kg of
body weight. Blood glucose levels
were determined using a Glucom-
eter Xceed (Abbott Diabetes
Care, UK). Blood glucose levels
were determined at indicated
time points and plotted as a func-
tion of time.
Histological examinations
determination of islet
histomorphometry
Mice were euthanized and his-
topathological pancreata samples
were excised and fixed in Bouin’s
solution for 4 h, washed in water
and then fixed in 10% neutral
buffered formalin. Fixed tissue
samples were processed and paraf-
fin embedded, sectioned and
stained.
For islet histomorphometry
sections were stained with anti-
insulin antibody (Abcam, UK).
The number of islets and the
number of pancreatic b-cells of
each islet were quantified, and
Figure 1. Body weight and non-fasting blood glucose tracking before and after STZ treatment. (A) Body
weight was measured every week and blood glucose was measured every other week before STZ treatment
in both groups, vehicle-treated (Control) and Epoxy-treated (Epoxy). (B) Body weight was measured every
day and blood glucose was measured every other day after STZ treatment in both groups, Control and Epoxy.
No signiﬁcant differences were detected.
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quantitative islet histomorph-
ometry was performed as previ-
ously described using ImageJ
software (NIH, USA).11
b-cell proliferation was
detected by BrdU incorporation
and double detection of BrdU/
insulin (Anti-BrdU, Abcam,
UK), a minimum of 1,000
b-cells were counted per pan-
creas. b-cell death was detected
by double staining of TUNEL
(Promega, USA) and insulin, a
minimum of 1,000 b-cells were
counted per pancreas, as previ-
ously described (3, 17).
Statistical analysis
Statistical analysis of data was
performed using the Graph Pad
Prism4 (GraphPad Software,
Inc., La Jolla, CA, USA). Distri-
bution of variables was checked
using the Kolmogorov-Smirnov
test. When a variable was dis-
tributed normally, data were
presented as mean § SD. Com-
parisons between 2 groups were
done by unpaired Students t-
test, and comparisons between
more than 2 groups were per-
formed by ANOVA followed by
Tukey’s Multiple Comparison
Test. Differences were considered significant at P < 0.05.
Results
Effects of epoxypukalide treatment on pancreatic b-cells
In this study, we have used a STZ-diabetic mouse model to
investigate the effects of Epoxy on glucose metabolism. STZ is
an alkylating agent that causes DNA damage in pancreatic b-cells
leading to b-cell damage and lower insulin production.8,12,13
First, we determined if Epoxypukalide had an impact on body
weight or glucose before STZ treatment. Therefore, we moni-
tored body weight once a week and non-fasting blood glucose
every other week. Body weight and glucose levels were similar in
both Control and Epoxy groups during the duration of the treat-
ment and before STZ treatment (Fig. 1A-B). Epoxy injections
did not have a harmful effect on mice, they looked perfectly
healthy, and they ate, drank and behaved normally. Furthermore,
we tracked body weight daily and non-fasting glucose every other
day for a week after STZ treatment, observing no-differences
between both groups (Fig. 1C-D).
To evaluate the impact of Epoxy on pancreatic b-cells treated
with STZ, we determined the number of islets and the number
of pancreatic b-cells of each islet in Control and Epoxy treated
mice. We used a group of no-STZ treated mice as a control of
STZ effect on b-cell area. Islet numbers were similar in Epox-
yCSTZ versus ControlCSTZ pancreata (0.19§ 0.02 islets/ mm2
vs. 0.18 § 0.02 islets/ mm2) but they were significantly different
to no-STZ treated pancreata (0.46 § 0.04 islets/mm2). Interest-
ingly, STZ treatment reduced b-cell number by half; this reduc-
tion was partially prevented by Epoxy since there was a significant
30% increase in b-cell number in EpoxyCSTZ versus Con-
trolCSTZ pancreata (Fig. 2A-C).
b-cell mass can be increased by augmented proliferation and/
or decreased b-cell death. To understand how b-cell number was
increased in Epoxy treated mice we quantified both. b-cell death
was detected by TUNEL staining, and proliferation by measur-
ing BrdU incorporation in insulin-positive cells. Our results
showed a 50% decrease in b-cell death in Epoxy treated b-cells
(Fig. 3A-B), and a 2-fold increase in b-cell proliferation
(Fig. 3C-D). Interestingly, this proliferative effect is specific on
pancreatic b-cells, since other endocrine cells as a-cells showed
similar proliferation in both conditions (0.04 § 0.03 % vs. 0.09
§ 0.05 %; p D 0.49). These results support the view that Epoxy
is an inhibitor of b-cell apoptosis under STZ toxicity, and it
enhances b-cell proliferation in vivo.
Figure 2. Quantitative islet histomorphometry in mice treated with epoxypukalide. Histomorphometry on pan-
creata sections was performed in mice without STZ or Epoxy treatment (no-STZ treated mice), in mice treated
with STZ plus vehicle (ControlCSTZ)and mice treated with STZ plus Epoxy (EpoxyCSTZ). (A) Average b-cell
number per islet. (B) Average b-cell number per islet per pancreas area (mm2). (C) Representative insulin-
stained islets from ControlCSTZ and EpoxyCSTZ treated mice (scale bar D 50 mm). N D 8-10 mice per group.
*P < 0.05 relative to no-STZ treatment group; #P < 0.05 relative to ControlCSTZ group.
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Effects of epoxypukalide
treatment on glucose
homeostasis
To investigate whether in vivo
b-cell expansion was having an
impact on glucose homeostasis,
we measured non-fasting plasma
insulin levels and glucose toler-
ance in STZ-mice treated with
vehicle or Epoxy. As shown in
Figure 4A, non-fasting plasma
insulin levels exhibited a 2-fold
augment in Epoxy treated mice
compared to Control mice.
These results nicely correlated to
b-cell expansion data shown in
Figure 2.
On the other hand, glucose
tolerance measured by IP-GTT
was significantly improved in
Epoxy-treated mice compared to
control mice (Fig. 4). Non-dia-
betic mice were used to establish
the levels of normal glucose tol-
erance. These data are in good
agreement with those observed
for plasma insulin levels in
Epoxy-treated mice. Taken
together, these results suggest that
Epoxy is a potential treatment for
b-cell preservation and diabetes
prevention.
Discussion
Epoxypukalide (Epoxy) is a
natural compound firstly isolated
by Ksebati et al from the gorgo-
nian Leptogorgia setacea.14 Since
then, different groups have identi-
fied and purified Epoxy and other
members of the furanocembrano-
lides family. In 2007, Dorta et al.
reported their isolation from
specimens from the genus Lepto-
gorgia collected around the Isth-
mus of Panama;15 and Grote
et al. also isolated Epoxy from the
soft coral Litophyton arboretum.16
Although Epoxy has not yet been
obtained by synthesis, furanocem-
branolides are also a popular tar-
get for total synthesis.17,18
In this manuscript, we have
shown for the first time that Epoxy
Figure 3. b-cell death and proliferation in mice treated with epoxypukalide. (A) Quantiﬁcation of b-cell apo-
ptosis (measured by TUNEL) in Control and Epoxy treated STZ-diabetic mice (N D 7-10). (B) Representative pic-
tures of insulin and TUNEL staining. (C) Quantiﬁcation of b-cell proliferation (measured by BrdU incorporation)
in Control and Epoxy treated STZ-diabetic mice (N D 6-10). (D) Representative pictures of insulin and BrdU
staining (scale bar D 50 mm). *P< 0.05 relative to control group.
Figure 4. Effect of epoxypukalide treatment on glucose metabolism. (A) Non-fasting plasma insulin was mea-
sured in Control and Epoxy treated STZ-diabetic mice. N D 8-10 mice per group. (B) Glucose tolerance test
was measured in Control and Epoxy treated STZ-diabetic mice, non-diabetic mice were used to establish the
levels of “normal glucose tolerance.” N D 6-7 mice per group. (C) Area under the curve. *P < 0.05 measured
by ANOVA.
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treatment prevents b-cell death and induces b-cell proliferation in a
preclinical diabetes model. Both events led to increased b-cell num-
ber and augmented insulinemia, which allowed a better glycemic
control. These results are nicely supported by our recent manuscript
reporting that Epoxy is an inductor of b-cell proliferation ex vivo,
and that it protects b-cells from basal and cytokine-induced
apoptosis.7
Of note, Epoxy does not induce proliferation in non-b-cell
proliferation in vivo, similar results have been observed in our
laboratory in primary cultures of rat pancreatic cells (unpublished
data). These data point out to a specific effect of Epoxy on the
pancreatic b-cell.
Most important, increased b-cell proliferation may involve
loss of differentiation and cell function failure, but despite its
positive effect on proliferation, Epoxy did not show a deleterious
effect on insulin production and secretion in Epoxy-treated
b-cells ex vivo.7 In the same way, now we have showed that
Epoxy treatment in STZ-diabetic mice did not exert negative
effects on pancreatic b-cell function, in fact, increased b-cell
mass produced higher plasma insulin levels improving glucose
control.
Interestingly, pancreatic b-cells are highly susceptible to oxi-
dative stress because of low antioxidant enzyme activity levels.19
We previously showed that Epoxy protected primary rat b-cell
cultures from a cocktail of pro-inflammatory cytokines including
IL-1b, IFN-g and TNF-a.7 Herein, we have showed that Epoxy
is protecting b-cell death from detrimental actions of local
inflammation on STZ pancreata. The diabetogenic action of
STZ is mediated mostly by reactive oxygen species (ROS).9 The
presence of the furan ring of Epoxy could decrease oxidative
stress by quenching damaging ROS.15 Taken together, these
results indicate that Epoxy protects b-cells from cytokine-medi-
ated oxidative stress. We are currently working on obtaining
Epoxy related compounds to examine further their therapeutic
potential for diabetes prevention and/or treatment.
In conclusion, our current data demonstrate that Epoxy can
significantly prevent experimental T1D in STZ-diabetic mice. In
addition, we provide evidences that its positive effects on glucose
metabolism are mediated by improved pancreatic b-cell mass
due to decreased cell death and increased proliferation.
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